Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-panBC umbrella study in metastatic breast cancer
2023-503629-20-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, giredestrant, inavolisib, atirmociclib, RO7881583 and 3 more in breast cancer, triple-negative breast cancer (TNBC), hormone receptor-positive breast cancer and 1 more (5 cohorts), sponsored by Roche. Primary endpoints: Objective response rate, Adverse events and laboratory abnormalities and 2 more. Planned start Jun 2018; status: authorised.
02
Drugs
atezolizumabgiredestrantinavolisibatirmociclibRO7881583
03
Conditions
breast cancertriple-negative breast cancer (TNBC)hormone receptor-positive breast cancerHER2-low breast cancer
Beyond the preview
Go deeper on 2023-503629-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503629-20-00.